BioLineRx Ltd. [NASDAQ: BLRX] plunged by -$0.32 during the normal trading session on Monday and reaching a high of $2.609 during the day while it closed the day at $2.28. The company report on October 30, 2020 that BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
– Enrollment to cease immediately; topline data anticipated in H1 2021-.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.
BioLineRx Ltd. stock has also loss -0.44% of its value over the past 7 days. However, BLRX stock has inclined by 14.00% in the 3 months of the year. Over the past six months meanwhile, it has gained 37.35% and gained 1.33% year-on date.
The market cap for BLRX stock reached $47.62 million, with 20.89 million shares outstanding and 19.77 million shares in the current float. Compared to the average trading volume of 4.67M shares, BLRX reached a trading volume of 3141648 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioLineRx Ltd. [BLRX]:
Maxim Group have made an estimate for BioLineRx Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2017. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on February 13, 2017, representing the official price target for BioLineRx Ltd. stock. Previously, the target price had yet another drop from $4 to $1, while Maxim Group kept a Hold rating on BLRX stock. On August 17, 2015, analysts decreased their price target for BLRX shares from 8 to 4.
The Average True Range (ATR) for BioLineRx Ltd. is set at 0.29 The Price to Book ratio for the last quarter was 1.54.
BLRX stock trade performance evaluation
BioLineRx Ltd. [BLRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.44. With this latest performance, BLRX shares gained by 43.40% in over the last four-week period, additionally plugging by 37.35% over the last 6 months – not to mention a drop of -10.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLRX stock in for the last two-week period is set at 61.00, with the RSI for the last a single of trading hit 58.30, and the three-weeks RSI is set at 60.38 for BioLineRx Ltd. [BLRX]. The present Moving Average for the last 50 days of trading for this stock 1.75, while it was recorded at 2.58 for the last single week of trading, and 1.80 for the last 200 days.
BioLineRx Ltd. [BLRX]: An insightful look at the core fundamentals
Return on Total Capital for BLRX is now -59.19, given the latest momentum, and Return on Invested Capital for the company is -55.78. Return on Equity for this stock declined to -67.23, with Return on Assets sitting at -45.89. When it comes to the capital structure of this company, BioLineRx Ltd. [BLRX] has a Total Debt to Total Equity ratio set at 31.32. Additionally, BLRX Total Debt to Total Capital is recorded at 23.85, with Total Debt to Total Assets ending up at 19.52. Long-Term Debt to Equity for the company is recorded at 22.65, with the Long-Term Debt to Total Capital now at 17.25.
Reflecting on the efficiency of the workforce at the company, BioLineRx Ltd. [BLRX] managed to generate an average of -$2,158,673 per employee.
Earnings per share (EPS) analysis for BioLineRx Ltd. [BLRX] stock
With the latest financial reports released by the company, BioLineRx Ltd. posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLRX.
BioLineRx Ltd. [BLRX]: Insider Ownership positions
Positions in BioLineRx Ltd. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 7 institutional holders increased their position in BioLineRx Ltd. [NASDAQ:BLRX] by around 445,727 shares. Additionally, 6 investors decreased positions by around 193,657 shares, while 7 investors held positions by with 2,537,502 shares. The mentioned changes placed institutional holdings at 3,176,886 shares, according to the latest SEC report filing. BLRX stock had 4 new institutional investments in for a total of 211,321 shares, while 3 institutional investors sold positions of 71,382 shares during the same period.